Findings point to a roadmap for using proteomic and genomic data along with Mendelian randomization, called “nature’s randomized trial,” to discover targets for other conditions.

Researchers at the Korean Institute of Life Sciences and Technology used MGI's DNBSEQ-T7 sequencer, among other tools, to engineer an efficient, miniaturized CRISPR-Cas gene-editing system that may be more easily packed into vectors for clinical applications.

Experts say proteogenomic findings can provide provide prognostic biomarkers and robust targets for drug development.

Talks at NanoString's fourth annual Spatial Genomics Summit shared early results from the CosMx Spatial Molecular Imager (SMI), which is slated for commercial rollout in the second half of 2022.

Advances in proteomics are improving cancer biomarker discovery, drug discovery, and drug target validation.

The symptom-based testing paradigm misses asymptomatic cases and transmission among undertested groups.

Research published within the past three years highlights a unique role for proteomics to aid critical areas of unmet need in rare disease populations.

Plasma and serum are brimming with potential protein biomarkers that can provide detailed information about health and disease mechanisms without the need for invasive medical procedures.

Talks and presentations at the virtual ESMO congress demonstrate that the field of cancer research is heading into a new era of tailored treatments.